| Market Cap | 333.36M | P/E | - | EPS this Y | 17.60% | Ern Qtrly Grth | - |
| Income | -80.74M | Forward P/E | -4.34 | EPS next Y | -4.80% | 50D Avg Chg | -20.00% |
| Sales | 58.44M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -8.00% |
| Dividend | N/A | Price/Book | 34.40 | EPS next 5Y | - | 52W High Chg | -46.00% |
| Recommedations | 1.60 | Quick Ratio | 6.36 | Shares Outstanding | 148.63M | 52W Low Chg | 67.00% |
| Insider Own | 3.68% | ROA | -25.66% | Shares Float | 126.72M | Beta | 1.32 |
| Inst Own | 50.11% | ROE | -127.64% | Shares Shorted/Prior | 14.65M/9.16M | Price | 4.30 |
| Gross Margin | -13.51% | Profit Margin | -138.15% | Avg. Volume | 1,223,720 | Target Price | 15.50 |
| Oper. Margin | -135.46% | Earnings Date | May 6 | Volume | 660,550 | Change | -2.05% |
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
| HC Wainwright & Co. | Buy | Apr 19, 24 |
| JMP Securities | Market Outperform | Apr 16, 24 |
| JMP Securities | Market Outperform | Mar 13, 24 |
| HC Wainwright & Co. | Buy | Mar 13, 24 |
| TD Cowen | Market Perform | Mar 12, 24 |
| JMP Securities | Market Outperform | Mar 12, 24 |
| Piper Sandler | Overweight | Feb 26, 24 |
| HC Wainwright & Co. | Buy | Feb 14, 24 |
| B of A Securities | Buy | Feb 9, 24 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| White Christopher G | Chief Business Offic.. Chief Business Officer | Feb 03 | Sell | 4.86 | 5,910 | 28,723 | 123,689 | 02/06/24 |
| Strassburger Philip C. | General Counsel General Counsel | Feb 03 | Sell | 4.86 | 6,029 | 29,301 | 161,493 | 02/06/24 |
| Ozden Rabia Gurses | Chief Medical Office.. Chief Medical Officer | Feb 03 | Sell | 4.86 | 6,346 | 30,842 | 153,054 | 02/06/24 |
| Notman Donald | Chief Financial Offi.. Chief Financial Officer | Feb 03 | Sell | 4.86 | 6,212 | 30,190 | 195,356 | 02/06/24 |
| Mattessich Antony C. | President and CEO President and CEO | Feb 03 | Sell | 4.86 | 19,642 | 95,460 | 588,701 | 02/06/24 |
| Notman Donald | Chief Financial Offi.. Chief Financial Officer | Jan 31 | Sell | 4.95 | 6,433 | 31,843 | 139,932 | 02/02/24 |
| Ozden Rabia Gurses | Chief Medical Office.. Chief Medical Officer | Jan 31 | Sell | 4.95 | 7,764 | 38,432 | 92,767 | 02/02/24 |
| Strassburger Philip C. | General Counsel General Counsel | Jan 31 | Sell | 4.95 | 6,831 | 33,813 | 109,218 | 02/02/24 |
| White Christopher G | Chief Business Offic.. Chief Business Officer | Jan 31 | Sell | 4.95 | 5,147 | 25,478 | 89,619 | 02/02/24 |
| Mattessich Antony C. | President and CEO President and CEO | Jan 31 | Sell | 4.95 | 18,338 | 90,773 | 427,943 | 02/02/24 |
| Mattessich Antony C. | President and CEO President and CEO | Aug 30 | Buy | 3.81 | 6,500 | 24,765 | 6,500 | 09/05/23 |
| Ozden Rabia Gurses | Chief Medical Office.. Chief Medical Officer | Jul 07 | Sell | 4.93 | 832 | 4,102 | 100,531 | 07/11/23 |
| White Christopher G | Chief Business Offic.. Chief Business Officer | Feb 06 | Sell | 4.24 | 5,829 | 24,715 | 94,766 | 02/08/23 |
| Ozden Rabia Gurses | Chief Medical Office.. Chief Medical Officer | Feb 06 | Sell | 4.24 | 6,416 | 27,204 | 101,363 | 02/08/23 |
| Notman Donald | Chief Financial Offi.. Chief Financial Officer | Feb 06 | Sell | 4.24 | 6,476 | 27,458 | 139,387 | 02/08/23 |
| Strassburger Philip C. | General Counsel General Counsel | Feb 06 | Sell | 4.24 | 6,181 | 26,207 | 109,071 | 02/08/23 |
| Mattessich Antony C. | President and CEO President and CEO | Feb 06 | Sell | 4.24 | 19,669 | 83,397 | 446,281 | 02/08/23 |
| SUMMER ROAD LLC | 10% Owner 10% Owner | Nov 07 | Buy | 3.50 | 7,328 | 25,648 | 6,122,089 | 11/09/22 |
| SUMMER ROAD LLC | 10% Owner 10% Owner | Sep 27 | Buy | 4.27 | 150,000 | 640,500 | 6,094,761 | 09/29/22 |
| LINDSTROM RICHARD L MD | Director Director | May 12 | Option | 1.22 | 9,469 | 11,552 | 99,469 | 05/16/22 |
| SUMMER ROAD LLC | 10% Owner 10% Owner | Feb 18 | Buy | 4.9 | 50,000 | 245,000 | 5,944,761 | 02/23/22 |
| SUMMER ROAD LLC | 10% Owner 10% Owner | Jan 27 | Buy | 5.2 | 5,500 | 28,600 | 5,894,761 | 01/31/22 |
| SUMMER ROAD LLC | 10% Owner 10% Owner | Jan 20 | Buy | 5.52 | 74,500 | 411,240 | 5,889,261 | 01/24/22 |
| SUMMER ROAD LLC | 10% Owner 10% Owner | Jan 13 | Buy | 6.07 | 50,000 | 303,500 | 5,814,761 | 01/18/22 |
| PEACOCK BRUCE | Director Director | Dec 07 | Option | 6.02 | 25,000 | 150,500 | 25,000 | 12/07/20 |